For most melanoma patients, Braftovi (encorafenib) and Mektovi (binimetinib) keep the cancer controlled for a median of about 14.9 months before the disease starts growing again. But that median hides a wide range of individual outcomes. At the five-year mark in the major clinical trial for this combination, 23% of patients still had no disease progression, and 35% were still alive. For people with certain favorable characteristics, those numbers climb even higher.
How long these drugs work for you depends heavily on the type of cancer being treated, your overall health markers at the start of treatment, and how your tumor eventually adapts to the drugs.
Duration of Response in Melanoma
The COLUMBUS trial, the landmark study behind this drug combination’s approval for BRAF-mutant melanoma, has now been followed for seven years. The results paint a detailed picture of what to expect over time.
Among patients who responded to treatment, the median duration of that response was 18.6 months. Disease control of some kind, whether a full or partial response or stable disease, was achieved in 92% of patients. Median melanoma-specific survival was 36.8 months, compared to 19.3 months for patients on an older single-drug approach.
The long-term numbers are where things get interesting. At seven years, 21% of patients on Braftovi plus Mektovi still had no cancer progression, and 27% were still alive. That compares to just 6% progression-free and 18% alive in the older-treatment group. These numbers suggest that roughly one in five patients gets a genuinely durable, long-lasting benefit from the combination.
What Improves Your Odds of a Longer Response
Not everyone responds equally. Two baseline factors stood out in the five-year analysis as strong predictors of how long treatment keeps working.
Patients who started treatment with normal LDH levels (a blood marker that tends to rise when cancer is more aggressive or widespread) had a five-year progression-free survival rate of 31% and a five-year overall survival rate of 45%. Those with both normal LDH and cancer in fewer than three organs did even better: 39% were still progression-free at five years, and 48% were alive. Compare that to the 23% and 35% rates for the overall group. If your oncologist has described your disease burden as relatively low, these numbers are the more relevant ones for you.
How It Works in Colorectal Cancer
Braftovi is also approved for BRAF V600E-mutant metastatic colorectal cancer, though in that setting the expected duration of benefit is shorter. In the BEACON trial, which studied Braftovi combined with a different partner drug (cetuximab, with or without Mektovi), median overall survival was 9.3 months, compared to 5.9 months with standard chemotherapy. The tumor shrank meaningfully in about 20 to 27% of patients.
Colorectal cancers with BRAF mutations are biologically more resistant to targeted therapy than melanomas with the same mutation, which is why the numbers look quite different between the two cancers. The benefit is real but more modest in duration.
Why the Drugs Eventually Stop Working
For most patients, the cancer eventually finds ways to grow despite the drugs. This is called acquired resistance, and it happens through several biological workarounds inside tumor cells.
The most common pattern involves the cancer reactivating the very growth-signaling pathway that Braftovi and Mektovi are designed to block. Tumor cells can do this by developing new mutations in related genes, by making extra copies of the BRAF gene itself, or by producing altered versions of the BRAF protein that the drugs can’t latch onto as effectively. In other cases, the cancer activates an entirely different signaling pathway to bypass the blockade altogether.
The immune environment around the tumor also shifts over time. Early in treatment, these drugs can actually make tumors more visible to the immune system, which contributes to their effectiveness. But as the cancer progresses, studies show a drop in immune cell activity within the tumor, including fewer cancer-killing immune cells and increased signs of immune exhaustion. This loss of immune engagement is part of why the drugs lose their grip.
These resistance mechanisms are one reason oncologists often discuss sequencing or combining targeted therapy with immunotherapy, as the two approaches can complement each other’s weaknesses.
How Quickly Patients See a Response
Braftovi and Mektovi tend to work fast when they work. These drugs block key growth signals directly, so tumor shrinkage often begins within the first few weeks of treatment. Imaging scans to assess response are typically done at regular intervals starting around two to three months in. The combination achieved disease control in over 92% of melanoma patients, meaning the vast majority saw at least some stabilization or shrinkage early on.
How Long Patients Stay on Treatment
You take Braftovi and Mektovi daily until the cancer progresses or side effects become unmanageable. In practice, most patients tolerate the combination well enough to continue. In the melanoma trial, only 5% of patients had to permanently stop treatment because of side effects, with bleeding and headache being the most common reasons. The discontinuation rate was somewhat higher in colorectal cancer (10%) and higher still in lung cancer trials (16%), where side effects like diarrhea, fatigue, nausea, and rash led more patients to stop.
For someone whose cancer is responding and who is tolerating the drugs, treatment continues indefinitely. There is no predetermined stopping point. Patients in the COLUMBUS trial who were still benefiting continued for years, which is reflected in those long-term survival statistics.